Salus Scientific Raises $10.1M Series A for Medtech Safety

Salus Scientific closed an oversubscribed $10.1M Series A on August 5, 2026, exceeding its original $8M target and closing ahead of schedule. The company did not disclose the lead investor, participating investors or valuation. The Charleston-area medical technology company, led by CEO and Co-Founder Todd O. Flohr and Founder William P. Buchanan, MD, FACC, develops occupational-wellness technology for physicians, nurses and technologists working in fluoroscopy-guided environments.

The financing will support commercial scale-up and expanded production and clinical infrastructure around Salus Scientific products including GLiFT, an endoskeleton support system, and AeroShield, a modular radiation-protection system. Salus Scientific has also said international expansion is underway, although specific markets have not been disclosed.

The larger story is not simply another medical-device company raising capital. Salus Scientific is building around a neglected piece of healthcare infrastructure: the physical sustainability of the people performing procedures. Medicine has become extraordinarily good at engineering the room around the patient. The humans standing in that room have occasionally been treated like replaceable hardware.

What Happened

Salus Scientific raised $10.1M in an oversubscribed Series A, surpassing its original $8M target. The financing was announced August 5, 2026, with investor identities and valuation undisclosed. That missing investor list matters for anyone mapping the capital behind Salus Scientific, but it should not obscure the more useful signal: the round attracted enough demand to close above the company's initial target.

Salus Scientific intends to use the Series A proceeds for commercial scale-up and expanded production and clinical infrastructure. The company is developing a broader portfolio around occupational protection in procedural medicine, with GLiFT and AeroShield at the center. The $10.1M Series A is the verified financing figure that matters here, without trying to inflate the story with historical funding numbers that have not been confirmed to the same standard.

Why Salus Scientific Exists

Salus Scientific has the kind of origin story medical-device investors tend to understand quickly because nobody needed a consultant to invent the pain point. William P. Buchanan, MD, FACC, an interventional cardiologist, developed chronic shoulder, neck and back pain after years of wearing heavy lead aprons. William P. Buchanan developed the original concept behind GLiFT to transfer that weight away from the shoulders, neck and back and toward the iliac crest, then brought the concept to Todd O. Flohr.

GLiFT became an endoskeleton support system designed around that problem. The underlying market need extends beyond 1 physician's experience. Salus Scientific cites data from the Society for Cardiovascular Angiography and Interventions indicating nearly 2/3 of interventional cardiologists develop major orthopedic problems during their careers. Healthcare has spent fortunes making procedures more sophisticated while accepting that the people performing them may accumulate occupational damage along the way. That contradiction is where Salus Scientific has planted its flag.

Even the company name fits unusually well. Salus takes its name from the Roman goddess associated with safety, health and well-being. After roughly 2,000 years, the branding has found a fairly literal product roadmap.

How GLiFT and AeroShield Address Occupational Risk

Salus Scientific is approaching occupational wellness as a system rather than treating orthopedic burden and radiation exposure as unrelated problems. GLiFT is designed to transfer the weight of lead protection from the shoulders, neck and back to the iliac crest. The objective is straightforward: retain necessary protection while reducing the physical burden associated with wearing heavy lead equipment during procedures.

AeroShield addresses radiation exposure from another direction. Salus Scientific describes AeroShield as a modular enhanced radiation protection device designed for room-level shielding across different specialties, procedures and room configurations. The company's portfolio also includes Salus Shield and PeRM radiation-monitoring tools. Together, the products position Salus Scientific beyond a single medical device and toward a broader occupational-protection platform for procedural environments.

That distinction matters commercially. Hospitals do not merely buy technology. They buy around workflow, staffing, physical space, clinical routines and institutional risk. A product that protects clinicians but makes the procedure materially harder creates its own adoption problem. Salus Scientific's stated design philosophy centers on avoiding that tradeoff. In medicine, a technically impressive device that annoys everybody using it can become a very expensive coat rack.

Why the $10.1M Series A Matters

Salus Scientific's $10.1M Series A reflects a broader opportunity emerging around healthcare workforce sustainability. Healthcare labor discussions usually orbit shortages, burnout, compensation and administrative burden. Physical occupational risk receives less attention despite its relationship to career longevity in procedural specialties. Salus Scientific is effectively arguing that clinician protection belongs inside the infrastructure conversation.

That creates a different commercial proposition. GLiFT is not simply competing for attention as another piece of equipment. Salus Scientific is asking hospitals and interventional practices to consider whether orthopedic burden, radiation exposure, workflow and clinician longevity should be evaluated as connected operational issues.

The fundraising also offers a useful lesson for medical-device founders. Salus Scientific started with a specific problem experienced directly by the customer, developed intellectual property around GLiFT, expanded its product architecture around adjacent occupational risks, and assembled leadership spanning engineering, sales, operations, finance, legal affairs and medical engagement. Capital likes a large market. It tends to become considerably more interested when the pain inside that market is obvious.

Leadership Behind Salus Scientific

Salus Scientific is led by CEO and Co-Founder Todd O. Flohr and Founder William P. Buchanan, MD, FACC. The current operating leadership identified in the company research includes President and CFO Keith Rosmarin, VP of Engineering Nicholas Tomczak, VP of Operations Ty Dawson, VP of Sales Michael Lankford, VP of Global Medical Affairs and Engagement Dan Lormon, and General Counsel Jon A. Wallace, R.Ph., J.D.

Salus Scientific's verified board representation includes William P. Buchanan, Ryan Majoria, MD, Ron Sancho and Will Martin. Will Martin joined the board in March 2026 and brings more than 20 years of medical-device experience, including serving as President and CEO of IRRAS before its acquisition by ClearPoint Neuro.

The distinction around Ron Sancho matters because the underlying research identified a naming discrepancy. An SEC Form D reportedly lists "Ryan Sancho," while business-registration and company information identify the director as Ron, or Ronald, Sancho. DevCuration uses Ron Sancho based on the supplied verification work. Richard S. Moore, Jr., MD, is associated historically with the GLiFT concept but could not be independently confirmed as a current director across the current records reviewed. Kenneth Rosenfield, MD, is identified as an external scientific advisor rather than company personnel.

What This Signals About the Medical Technology Market

Salus Scientific sits inside a larger shift in medical technology: healthcare infrastructure is increasingly being judged by what it does for the workforce as well as what it does for the patient. That does not mean every occupational-health device becomes a venture-scale company. It means persistent clinical problems once dismissed as part of the job can become addressable markets when technology, workflow design and institutional economics line up.

For Salus Scientific, the next phase is commercial rather than conceptual. The company has $10.1M in new financing, products aimed at identifiable occupational hazards, expanded production and clinical infrastructure on the agenda, and international expansion described as underway. Specific international markets have not been disclosed. Neither have Series A investors, valuation or precise commercial metrics. Those omissions leave important questions about adoption and financing composition unanswered.

Still, the strategic thesis is unusually easy to understand. If healthcare systems expect highly trained clinicians to spend careers performing sophisticated procedures around radiation while carrying protective equipment, protecting those clinicians becomes more than an ergonomic courtesy. It becomes infrastructure.

The Bigger Industry Shift

Salus Scientific's Series A points toward a category sitting between medical devices, occupational health, workforce sustainability and hospital infrastructure. The economic logic deserves attention. Experienced interventional specialists represent years of education, clinical training and institutional knowledge. Technologies designed to reduce occupational burden can therefore enter a conversation larger than equipment procurement: clinician retention, career longevity, workplace safety and procedural capacity.

That is why sophisticated operators should watch what happens after the financing rather than treating $10.1M as the finish line. Capital establishes that investors were willing to finance the next stage. Commercial adoption will determine whether occupational wellness develops into a durable purchasing category. Salus Scientific now has to translate an intuitively compelling problem into repeatable institutional adoption while scaling GLiFT, AeroShield and its broader protection portfolio.

Medicine has spent decades improving what happens on the table. Salus Scientific is betting that the market is finally ready to spend more attention on the people standing beside it.